A competition assay format was applied with 4 as a radioligand (replacing the initially used 5) to assess competition potency of test compounds that may reflect specificity against beta amyloid/tau aggregates in AD patient brain homogenates (i.e. skewed toward beta amyloid aggregates). The gene discussed is MAPT; the disease is Alzheimer disease.